Leucemia promielocítica de reciente diagnóstico. Tratamiento con trióxido de arsénico de producción nacional (Arsenin®)

Hernández Padrón, Carlos; Dorticós Balea, Elvira; Machín García, Sergio; Menéndez Veitía, Andrea; González Otero, Alejandro; Cano Izquierdo, Lissete; Espinosa Estrada, Edgardo; Simón Pita, Ana María; Amor Vigil, Ana María; Hernández Ramírez, Porfirio.
Rev. cuba. hematol. inmunol. hemoter ; 30(4): 346-359, oct.-dic. 2014.
Artigo em Espanhol | LILACS | ID: lil-735295

Documentos relacionados

  1. Tetra-arsenic tetra-sulfide enhances NK-92MI mediated cellular immunotherapy in all-trans retinoic acid-resistant acute promyelocytic leukemia.
  2. Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia.
  3. <i>FLT3</i>-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.
  4. [Three Waves of Arsenic Therapy for Leukemia and Related Innovations].
  5. The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA.
  6. Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia.
  7. Acute promyelocytic leukemia in children and adolescents.
  8. Outpatient oral treatment for acute promyelocytic leukemia.
  9. Outpatient oral treatment for acute promyelocytic leukemia.
  10. The simpler, the better: oral arsenic for acute promyelocytic leukemia.